PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
25949878-9	2015	This was marked tumor-inhibitory phenotype was associated with a significant reduction in the levels of MDSCs bearing the surface markers CD33, CD34 and CD11b in PEITC treated mice, indicating that overall tumor growth suppression by PEITC correlates with inhibition of MDSCs.	phenethyl isothiocyanate	162-167	CD33 antigen	Mus musculus	138-142
24227736-2	2013	Siglec-E is a mouse CD33-related Siglec that preferentially binds to sialic acid residues of the cellular glycocalyx.	N-Acetylneuraminic Acid	69-80	CD33 antigen	Mus musculus	20-24
23946390-12	2013	Exon 2 encodes the CD33 IgV domain that typically mediates sialic acid binding in SIGLEC family members.	N-Acetylneuraminic Acid	59-70	CD33 antigen	Mus musculus	19-23
9935073-6	1999	The bismuth-labeled CHX-A-DTPA-HuM195 construct was rapidly internalized into the cell in a time-dependent manner ranging from 50% at 1 h to 65% at 24 h. 205Bi/206Bi-labeled constructs were stable for at least 2 d in vitro in the presence of human serum at 37 degrees C. After injection into mice, there was no uptake or loss of bismuth to mouse tissues, which do not express CD33, or to the kidney, which has avidity for free bismuth.	N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-N,N',N',N'',N''-pentaacetic acid	20-30	CD33 antigen	Mus musculus	376-380
19933851-2	2009	CD33-related sialic acid binding Ig-like lectin receptors (Siglecs) have been implicated in the control of leukocyte responses.	N-Acetylneuraminic Acid	13-24	CD33 antigen	Mus musculus	0-4
17073742-2	2006	The CD33-related siglecs are a distinct subset mostly expressed in the innate immune system where they can function as inhibitory receptors by suppressing the signalling mediated by receptors coupled with ITAMs (immunoreceptor tyrosine-based activation motifs).	Tyrosine	227-235	CD33 antigen	Mus musculus	4-8
17073742-3	2006	CD33-related siglecs contain ITIMs (immunoreceptor tyrosine-based inhibitory motifs) that recruit and activate SHP-1 [SH2 (Src homology 2) domain-containing phosphatase-1] and SHP-2.	Tyrosine	51-59	CD33 antigen	Mus musculus	0-4
12773563-1	2003	Mouse CD33/Siglec-3 (mCD33) is the apparent ortholog of human CD33/Siglec-3 (hCD33), a member of the Siglec (sialic acid-binding Ig superfamily lectin) family of sialic acid-recognizing cell-surface lectins.	N-Acetylneuraminic Acid	109-120	CD33 antigen	Mus musculus	21-26
12773563-1	2003	Mouse CD33/Siglec-3 (mCD33) is the apparent ortholog of human CD33/Siglec-3 (hCD33), a member of the Siglec (sialic acid-binding Ig superfamily lectin) family of sialic acid-recognizing cell-surface lectins.	N-Acetylneuraminic Acid	162-173	CD33 antigen	Mus musculus	21-26
23866283-6	2013	The in vivo experiment showed that mice with AMoL had the most significant decrease in CD33(+)CD45(+) leukemia cells in peripheral blood and bone marrow and survived the longest after being treated with Ara-C (7 days) plus anti-CD47 monoclonal antibody (14 days) (P < 0.01).	Cytarabine	203-208	CD33 antigen	Mus musculus	87-91
20626609-11	2010	Apocynin treatment of LDLR-null mice preserved (P<0.05) maximal intracavernosal pressure, and reversed (P<0.05) the abnormalities in protein expressions of gp67(phox) and gp47(phox) , 4-HNE, P-VASP-Ser-239, and eNOS uncoupling in the penis.	4-hydroxy-2-nonenal	190-195	CD33 antigen	Mus musculus	162-166
20626609-11	2010	Apocynin treatment of LDLR-null mice preserved (P<0.05) maximal intracavernosal pressure, and reversed (P<0.05) the abnormalities in protein expressions of gp67(phox) and gp47(phox) , 4-HNE, P-VASP-Ser-239, and eNOS uncoupling in the penis.	Serine	204-207	CD33 antigen	Mus musculus	162-166
18326813-0	2008	Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.	OZOGAMICIN	112-122	CD33 antigen	Mus musculus	79-83
17272508-1	2007	CD33-related Siglecs (CD33rSiglecs) are a family of sialic acid-recognizing lectins on immune cells whose biologic functions are unknown.	N-Acetylneuraminic Acid	52-63	CD33 antigen	Mus musculus	0-4
11171044-0	2001	mSiglec-E, a novel mouse CD33-related siglec (sialic acid-binding immunoglobulin-like lectin) that recruits Src homology 2 (SH2)-domain-containing protein tyrosine phosphatases SHP-1 and SHP-2.	N-Acetylneuraminic Acid	46-57	CD33 antigen	Mus musculus	25-29
9935073-0	1999	Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.	bismuth cyclohexylbenzyl dtpa	15-44	CD33 antigen	Mus musculus	86-90
9935073-6	1999	The bismuth-labeled CHX-A-DTPA-HuM195 construct was rapidly internalized into the cell in a time-dependent manner ranging from 50% at 1 h to 65% at 24 h. 205Bi/206Bi-labeled constructs were stable for at least 2 d in vitro in the presence of human serum at 37 degrees C. After injection into mice, there was no uptake or loss of bismuth to mouse tissues, which do not express CD33, or to the kidney, which has avidity for free bismuth.	Bismuth	4-11	CD33 antigen	Mus musculus	376-380
34526055-6	2021	RESULTS: We found that mild central nervous system (CNS) sulfatide losses within myelinating cells are sufficient to activate disease-associated microglia and astrocytes, and to increase the expression of AD risk genes (e.g., Apoe, Trem2, Cd33, and Mmp12), as well as previously established causal regulators of the immune/microglia network in late-onset AD (e.g., Tyrobp, Dock, and Fcerg1), leading to chronic AD-like neuroinflammation and mild cognitive impairment.	Sulfoglycosphingolipids	57-66	CD33 antigen	Mus musculus	239-243
35452678-13	2022	The unique CD33 and Siglec-8 ligand, RPTPzetaS3L, may contribute to Alzheimer"s disease progression.	rptpzetas3l	37-48	CD33 antigen	Mus musculus	11-15
32803224-2	2020	CD33 (Siglec-3) is a transmembrane sialic acid-binding receptor on the surface of microglial cells.	N-Acetylneuraminic Acid	35-46	CD33 antigen	Mus musculus	0-4
33007530-3	2021	Sialic acid-binding immunoglobulin-like lectin (Siglec)-9 and its murine homolog Siglec-E are sialic acid-recognizing inhibitory receptors from the CD33-related Siglec-family and mainly expressed on myeloid cells.	N-Acetylneuraminic Acid	94-105	CD33 antigen	Mus musculus	148-152
32803224-2	2020	CD33 (Siglec-3) is a transmembrane sialic acid-binding receptor on the surface of microglial cells.	N-Acetylneuraminic Acid	35-46	CD33 antigen	Mus musculus	6-14
32803224-10	2020	Overall, our data indicate that CD33 is a viable target for AAV-based knock-down strategies to reduce ad pathology.	CHEMBL2031461	60-63	CD33 antigen	Mus musculus	32-36
32661096-7	2020	A CD33-targeting second-generation TriKE induced stronger and more specific NK cell proliferation without T-cell stimulation, enhanced in vitro NK cell activation and killing of CD33-expressing targets, and improved tumor control in preclinical mouse models.	trike	35-40	CD33 antigen	Mus musculus	2-6
32661096-7	2020	A CD33-targeting second-generation TriKE induced stronger and more specific NK cell proliferation without T-cell stimulation, enhanced in vitro NK cell activation and killing of CD33-expressing targets, and improved tumor control in preclinical mouse models.	trike	35-40	CD33 antigen	Mus musculus	178-182
31815204-2	2019	Divergent features between human CD33 (hCD33) and murine CD33 (mCD33) include a unique transmembrane lysine in mCD33 and cytoplasmic tyrosine in hCD33.	tyrosyl-lysine	101-107	CD33 antigen	Mus musculus	40-44
31815204-2	2019	Divergent features between human CD33 (hCD33) and murine CD33 (mCD33) include a unique transmembrane lysine in mCD33 and cytoplasmic tyrosine in hCD33.	tyrosyl-lysine	101-107	CD33 antigen	Mus musculus	63-68
31815204-2	2019	Divergent features between human CD33 (hCD33) and murine CD33 (mCD33) include a unique transmembrane lysine in mCD33 and cytoplasmic tyrosine in hCD33.	tyrosyl-lysine	101-107	CD33 antigen	Mus musculus	111-116
31815204-2	2019	Divergent features between human CD33 (hCD33) and murine CD33 (mCD33) include a unique transmembrane lysine in mCD33 and cytoplasmic tyrosine in hCD33.	Tyrosine	133-141	CD33 antigen	Mus musculus	40-44
31815204-2	2019	Divergent features between human CD33 (hCD33) and murine CD33 (mCD33) include a unique transmembrane lysine in mCD33 and cytoplasmic tyrosine in hCD33.	Tyrosine	133-141	CD33 antigen	Mus musculus	63-68
31815204-5	2019	Notably, cell surface expression of mCD33 is entirely dependent on Dap12 due to an interaction with the transmembrane lysine in mCD33.	tyrosyl-lysine	118-124	CD33 antigen	Mus musculus	36-41
31815204-5	2019	Notably, cell surface expression of mCD33 is entirely dependent on Dap12 due to an interaction with the transmembrane lysine in mCD33.	tyrosyl-lysine	118-124	CD33 antigen	Mus musculus	128-133
30951849-8	2019	In conditions without amyloid (human microglial cells in vitro, aged wild-type mice), Curc-lo similarly decreased CD33 and increased TREM2.	curc-lo	86-93	CD33 antigen	Mus musculus	114-118
29844237-3	2018	Ongoing work has shown that growth of 15253 in cytidine monophospho-N-acetylneuraminic acid (CMP-Neu5Ac)-containing medium enables binding to CD33/Siglec-3, a cell surface receptor that binds sialic acid, suggesting that lactose termini on LOSs of intact gonococci can be sialylated.	cytidine monophospho-n-acetylneuraminic acid	47-91	CD33 antigen	Mus musculus	142-146
29844237-3	2018	Ongoing work has shown that growth of 15253 in cytidine monophospho-N-acetylneuraminic acid (CMP-Neu5Ac)-containing medium enables binding to CD33/Siglec-3, a cell surface receptor that binds sialic acid, suggesting that lactose termini on LOSs of intact gonococci can be sialylated.	cytidine monophospho-n-acetylneuraminic acid	47-91	CD33 antigen	Mus musculus	147-155
29844237-3	2018	Ongoing work has shown that growth of 15253 in cytidine monophospho-N-acetylneuraminic acid (CMP-Neu5Ac)-containing medium enables binding to CD33/Siglec-3, a cell surface receptor that binds sialic acid, suggesting that lactose termini on LOSs of intact gonococci can be sialylated.	cytidine-5'-monophosphosialic acid	93-103	CD33 antigen	Mus musculus	142-146
29844237-3	2018	Ongoing work has shown that growth of 15253 in cytidine monophospho-N-acetylneuraminic acid (CMP-Neu5Ac)-containing medium enables binding to CD33/Siglec-3, a cell surface receptor that binds sialic acid, suggesting that lactose termini on LOSs of intact gonococci can be sialylated.	cytidine-5'-monophosphosialic acid	93-103	CD33 antigen	Mus musculus	147-155
29844237-3	2018	Ongoing work has shown that growth of 15253 in cytidine monophospho-N-acetylneuraminic acid (CMP-Neu5Ac)-containing medium enables binding to CD33/Siglec-3, a cell surface receptor that binds sialic acid, suggesting that lactose termini on LOSs of intact gonococci can be sialylated.	N-Acetylneuraminic Acid	192-203	CD33 antigen	Mus musculus	142-146
29844237-3	2018	Ongoing work has shown that growth of 15253 in cytidine monophospho-N-acetylneuraminic acid (CMP-Neu5Ac)-containing medium enables binding to CD33/Siglec-3, a cell surface receptor that binds sialic acid, suggesting that lactose termini on LOSs of intact gonococci can be sialylated.	N-Acetylneuraminic Acid	192-203	CD33 antigen	Mus musculus	147-155
29844237-3	2018	Ongoing work has shown that growth of 15253 in cytidine monophospho-N-acetylneuraminic acid (CMP-Neu5Ac)-containing medium enables binding to CD33/Siglec-3, a cell surface receptor that binds sialic acid, suggesting that lactose termini on LOSs of intact gonococci can be sialylated.	Lactose	221-228	CD33 antigen	Mus musculus	142-146
29844237-3	2018	Ongoing work has shown that growth of 15253 in cytidine monophospho-N-acetylneuraminic acid (CMP-Neu5Ac)-containing medium enables binding to CD33/Siglec-3, a cell surface receptor that binds sialic acid, suggesting that lactose termini on LOSs of intact gonococci can be sialylated.	Lactose	221-228	CD33 antigen	Mus musculus	147-155
32303428-11	2020	In vivo infusion of mbIL-21 NK cells in AML PDX mice, treated with CD33mAb, reduced the tumor burden.	mbil	20-24	CD33 antigen	Mus musculus	67-71
28986815-12	2018	Compared with the control and ADM groups, the expression of CD34+CD38-CD96+ and CD34+CD38-CD33+ in the two CZG groups decreased (P<0.05).	CHEMBL4441783	107-110	CD33 antigen	Mus musculus	90-94
27535972-0	2016	In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia.	Thorium	55-62	CD33 antigen	Mus musculus	41-45
27535972-3	2016	We describe the preparation and use of a CD33-targeted thorium-227 conjugate (CD33-TTC), which binds to the sialic acid receptor CD33 for the treatment of acute myeloid leukemia (AML).	Thorium	55-62	CD33 antigen	Mus musculus	41-45
27535972-3	2016	We describe the preparation and use of a CD33-targeted thorium-227 conjugate (CD33-TTC), which binds to the sialic acid receptor CD33 for the treatment of acute myeloid leukemia (AML).	Thorium	55-62	CD33 antigen	Mus musculus	78-82
27535972-3	2016	We describe the preparation and use of a CD33-targeted thorium-227 conjugate (CD33-TTC), which binds to the sialic acid receptor CD33 for the treatment of acute myeloid leukemia (AML).	Thorium	55-62	CD33 antigen	Mus musculus	78-82
27535972-4	2016	A chelator was conjugated to the CD33-targeting antibody lintuzumab via amide bonds, enabling radiolabeling with the alpha-emitter 227Th.	Amides	72-77	CD33 antigen	Mus musculus	33-37